| abstract |
This invention relates to the analogues' compounds of 2-aminoindane being able to make selective associates with the dopamine D3 receptors in vitro. There are described compounds and their pharmaceutically acceptable salts of Formula (I) [Figure] wherein R1 and R2 are independently chosen from OSO2CF3, OSO2CH3, SOR5, CO2R5, CONH2, CONR5R6, COR5, CN, SO2NH2, SO2NR5R6, SO2 R5, -OCO-(C1 -C6 alkyl), -NCO-(C1 -C6 alkyl), -CH2O-(C1 -C6 alkyl), -CH2OH, -CO-Aryl, -NHSO2-Aryl, -NHSO2-(C1 -C6 alkyl); R3 and R4 are independently chosen from C1 -C8 alkyl, C2 -C4 alkenyl, C3 -C8 cycloalkyl; R5 is hydrogen, C1 -C8 alkyl, C2 -C4 alkenyl or C3 -C8 alkynyl; and R6 is C1 -C8 alkyl, C2 -C8 alkynyl, C3 -C8 cycloalkyl, or Aryl. Aryl is defined as having 6 to 12 carbon atoms optionally substituted with 1 to 3 hydroxy, fluoro, chloro or bromo groups. The compounds (I) may be used for the manufacture of a medicament for use in treating a central nervous system disorder associated with dopamine D3 receptor activity. The mentioned disorders include schizophrenia, mania, depression, geriatric disorders, drug abuse and addiction, Parkinson's disease, sleep disorders, circadian rhythm disorders, anxiety disorders and dementia. |